Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Convertible Debt (2016)

GT Biopharma (GTBP) has disclosed Convertible Debt for 3 consecutive years, with $11.1 million as the latest value for Q4 2016.

  • On a quarterly basis, Convertible Debt rose 1460.78% to $11.1 million in Q4 2016 year-over-year; TTM through Dec 2016 was $11.1 million, a 1460.78% increase, with the full-year FY2016 number at $11.1 million, up 1460.78% from a year prior.
  • Convertible Debt was $11.1 million for Q4 2016 at GT Biopharma, up from $400000.0 in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $11.1 million in Q4 2016 to a low of $128000.0 in Q1 2014.
  • A 3-year average of $2.0 million and a median of $553000.0 in 2016 define the central range for Convertible Debt.
  • Peak YoY movement for Convertible Debt: increased 12.62% in 2015, then soared 1460.78% in 2016.
  • GT Biopharma's Convertible Debt stood at $634000.0 in 2014, then grew by 12.62% to $714000.0 in 2015, then skyrocketed by 1460.78% to $11.1 million in 2016.
  • Per Business Quant, the three most recent readings for GTBP's Convertible Debt are $11.1 million (Q4 2016), $400000.0 (Q3 2016), and $528000.0 (Q2 2016).